文献速递临床试验与 GCP基础与转化研究

早期乳腺癌保乳术中单剂量靶向术中放疗的长期生存与局部控制:TARGIT-A随机临床试验

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.
PubMed 文献 · BMJ · 2020-08-19

TARGIT-A试验在10国32中心纳入2298例45岁以上早期乳腺癌患者,随机接受风险适配的保乳术中单剂量靶向术中放疗(TARGIT-IORT)或术后全乳外照射放疗(EBRT)。中位随访8.6年显示两组局部无复发生存、无乳房切除生存、远处无病生存、总生存及乳腺癌死亡率均无显著差异,TARGIT-IORT组其他原因死亡率显著更低。

要点

  • 保乳术中单剂量TARGIT-IORT在符合试验标准的早期乳腺癌患者中可替代术后全乳EBRT。
  • 长期随访中两组肿瘤学结局无显著差异,TARGIT-IORT组非乳腺癌死亡率更低。
  • 拟行保乳手术的合格患者应与医生讨论TARGIT-IORT选项。

核心结论

  • 对符合试验筛选标准的早期乳腺癌患者,保乳术中即时单剂量风险适配TARGIT-IORT是EBRT的有效替代方案。
  • 长期肿瘤控制疗效与EBRT相当,且非乳腺癌死亡率更低。
  • 拟行保乳手术的合格患者应讨论TARGIT-IORT。

研究设计与样本

  • 前瞻性、开放标签、随机对照临床试验,在英国、欧洲、澳大利亚、美国、加拿大10国32中心开展。
  • 2298例45岁及以上、浸润性导管癌≤3.5 cm、cN0-N1、适合保乳的女性,保乳术前按1:1随机分组,按中心分层区组。
  • 随机分配至TARGIT-IORT组1140例或EBRT组1158例。
  • TARGIT-IORT组约80%患者仅接受术中放疗,约20%因术后病理发现未预期高危因素补充EBRT。

主要发现

  • 五年完整随访局部复发风险TARGIT-IORT组2.11%,EBRT组0.95%,差异1.16%(90%CI 0.32–1.99),达到非劣效界值2.5%。
  • 前五年TARGIT-IORT组局部复发多13例(24/1140 vs 11/1158),死亡少14例(42/1140 vs 56/1158)。
  • 长期随访(中位8.6年,最长18.90年,IQR 7.0–10.6)局部无复发生存HR 1.13(95%CI 0.91–1.41,P=0.28)。
  • 无乳房切除生存HR 0.96(0.78–1.19,P=0.74),远处无病生存HR 0.88(0.69–1.12,P=0.30)。
  • 总生存HR 0.82(0.63–1.05,P=0.13),乳腺癌死亡HR 1.12(0.78–1.60,P=0.54),其他原因死亡HR 0.59(0.40–0.86,P=0.005)。

关键数值与推荐

  • 非劣效界值为两组五年局部复发率绝对差2.5%。
  • 五年局部复发风险TARGIT-IORT组2.11%,EBRT组0.95%,差异1.16%(90%CI 0.32–1.99)。
  • 长期随访局部无复发生存HR 1.13(95%CI 0.91–1.41,P=0.28)。
  • 其他原因死亡HR 0.59(95%CI 0.40–0.86,P=0.005)。

临床怎么用

  • 对符合TARGIT-A筛选标准的早期乳腺癌患者,保乳术中可考虑单剂量TARGIT-IORT替代术后全乳EBRT。
  • 约20%患者术后病理发现高危因素时需补充EBRT。
  • 拟行保乳手术时应与合格患者讨论TARGIT-IORT选项。

局限性

  • 开放标签设计。
  • TARGIT-IORT组约20%患者补充EBRT,非纯术中放疗。
  • 五年局部复发率绝对差虽在非劣效界值内,但TARGIT-IORT组数值更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer. DESIGN: Prospective, open label, randomised controlled clinical trial. SETTING: 32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada. PARTICIPANTS: 2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1, eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre) to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy (EBRT). INTERVENTIONS: Random allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients (around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found unsuspected higher risk factors (around 20% of patients). MAIN OUTCOME MEASURES: Non-inferiority with a margin of 2.5% for the absolute difference between the five year local recurrence rates of the two arms, and long term survival outcomes. RESULTS: Between 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v 11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.74), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.78 to 1.60, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005). CONCLUSION: For patients with early breast cancer who met our trial selection criteria, risk adapted immediate single dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned. TRIAL REGISTRATION: ISRCTN34086741, NCT00983684.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ. 2020. PMID: 32816842. doi:10.1136/bmj.m2836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。